The in vitro metabolism of rivaroxaban, a novel, oral, direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders, was investigated in several species, including humans. The objective of this study was to elucidate metabolite structures and identify the metabolic pathways to provide support for in vivo safety and clinical studies. 
There is a need for new oral anticoagulants such as rivaroxaban (Xarelto) because the use of currently available anticoagulants is limited by parenteral administration or the need for frequent coagulation monitoring and dose adjustment (Kubitza and Haas, 2006) because of unpredictable pharmacology and drug and food interactions. Factor Xa (FXa) is a particularly attractive target for effective anticoagulation because it acts at the convergence point of the intrinsic and extrinsic coagulation pathways (Walenga et al., 2003; Shimizu et al., 2004; Kubitza and Haas, 2006) , catalyzing the conversion of prothrombin to thrombin (Mann et al., 2003) . Inhibiting FXa will potentially block thrombin generation and diminish thrombin-mediated activation of coagulation.
Rivaroxaban is a novel, oral, direct FXa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders (Fig. 1 ). More recently, it has received approval in Canada and in the European Union for use in the prevention of venous thromboembolism in patients undergoing elective total hip or knee replacement surgery. It is a highly selective, orally active FXa inhibitor, which inhibits human free FXa (K i 0.4 nM). In addition, rivaroxaban inhibits prothrombinase activity (IC 50 2.1 nM) and fibrin-associated FXa activity (IC 50 92 nM), independently of antithrombin Perzborn et al., 2005) . In vitro, rivaroxaban has been shown to inhibit thrombin generation and prolong clotting times Perzborn et al., 2005) .
Metabolism studies are essential in the drug discovery and development process and are important to support the safety studies and the clinical development of drug candidates. Pharmacokinetic studies in rats and dogs (Weinz et al., 2005) and in humans (Weinz et al., 2009) have demonstrated that rivaroxaban was absorbed rapidly after oral dosing, had a favorable and predictable pharmacokinetic profile, and was excreted rapidly via renal and faecal/biliary routes.
The current study was designed to identify all metabolites and elucidate the metabolic pathways of rivaroxaban in vitro using liver preparations (microsomes and hepatocytes) from rats, dogs, and humans. In human-derived preparations, both radiolabeled [
14 C]rivaroxaban and unlabeled derivatives of rivaroxaban were studied, to establish the complete metabolism of rivaroxaban in vitro and com-plement the in vivo metabolism studies of the drug (Weinz et al., 2009 ).
Materials and Methods
Reference Compounds and Chemicals. [
14 C]Rivaroxaban ([ 14 C]BAY 59-7939), with specific activity of 2.69 MBq/mg, enantiomeric purity Ͼ99% enantiomeric excess, and UV and radiochemical purity Ͼ99%, was synthesized by the Isotope Chemistry Laboratory of Bayer HealthCare AG (Wuppertal, Germany) (Pleiss et al., 2006) . Unlabeled rivaroxaban (BAY 59-7939) and the metabolites M-4 (Pleiss et al., 2006) , racemic M-1, M-2, M-7, M-9, M-14 (5-chlorothiophene-2-carboxamide), the HCl salt of M-15, M-16, M-17, and M-18 were synthesized at Bayer HealthCare AG and Bayer Schering Pharma AG (Berlin, Germany). M-13 (5-chlorothiophene-2-carboxylic acid) was purchased from Sigma-Aldrich (Steinheim, Germany). Other reagents and solvents were obtained from commercial sources and were of analytical grade or higher purity.
Enzymes. Pooled human liver microsomes (pool of 14) and liver cytosol were purchased from Cytonet (Weinheim, Germany), and fresh primary human hepatocytes isolated from surgical waste tissue were purchased from Cytonet or Hepacult (Unterföhring, Germany). Liver microsomes and hepatocytes from Wistar rat and Beagle dog were prepared or isolated in-house according to standard procedures; they were well characterized toward a variety of standard substrates and exhibited good enzymatic activities. All microsomal preparations were stored at Ϫ80°C, at a concentration of 20 mg/ml, in 50 mM potassium phosphate buffer (pH 7.4) and 250 mM sucrose. Recombinant monoamine oxidases MAO-A and MAO-B and recombinant CYP3A4 were purchased from BD Biosciences (Woburn, MA were used as negative controls. After up to 2 h, incubations were stopped with acetonitrile and frozen at Ϫ20°C until analyzed. Samples were centrifuged at approximately 10,000g for 5 min at room temperature before analysis, to precipitate proteins. An aliquot of the supernatant was removed to control the recovery of radioactivity by liquid scintillation counting; the supernatant was then directly used for high-performance liquid chromatography (HPLC) analysis without further workup. Liver cytosol and recombinant MAO were incubated under conditions similar to those for liver microsomes. 
Hepatocytes. [
14 C]Rivaroxaban was incubated with Wistar rat, Beagle dog, and human hepatocytes in sandwich cultures according to a published procedure (Kern et al., 1997) . Primary fresh hepatocytes were cultured and incubated with 10 g/ml (approximately 23 M) [
14 C]rivaroxaban, added from a 1 mg/ml stock solution dissolved in acetonitrile. Preparation of samples for analysis was similar to that described for liver microsomes.
Metabolite Profiling and Identification. Metabolite profiling. The samples obtained from in vitro incubations were analyzed by reversed-phase HPLC coupled with either UV and off-line radioactivity detection or UV and mass spectrometry (MS) detection. An HP1100 system, consisting of a pump, an autosampler, a column oven (at 40°C), and a diode array detector from Agilent Technologies (Waldbronn, Germany), was used for HPLC. Samples were analyzed on a Nucleosil 100-5 C8 HD 125 ϫ 2 mm column protected by a Nucleosil 100-5 C8 HD 8 ϫ 3 mm guard column (Macherey-Nagel, Düren, Germany). Metabolites were separated with a gradient of 50 mM aqueous ammonium acetate, pH 4.8 (solvent A) and acetonitrile (solvent B) at a flow rate of 0.45 ml/min. The gradient was 0% solvent B at 0 min, linear to 5% solvent B at 1 min, linear to 40% solvent B at 29 min, and linear to 80% solvent B at 30 min. For off-line radioactivity detection, the HPLC effluent was fractionated into 96-well plates, with a sampling rate of 10 s; liquid scintillation cocktail Ultima Flo AP (150 l/well) was added simultaneously using a Gilson robotic liquid handler (Abimed, Langenfeld, Germany). The plates were sealed with a heat-sealing foil and analyzed by liquid scintillation counting using a Wallac 1450 Microbeta Plus scintillation counter (Wallac, Turku, Finland) . Radiochromatograms were reconstructed from the liquid scintillation data using the Gina Star program (Raytest, Straubenhardt, Germany). The limit of detection using this off-line radioactivity detection with a signal/noise ratio of 3 was approximately 50 dpm on column. The radioactivity of other liquid samples was measured by liquid scintillation counting using a liquid scintillation spectrometer (Tri-Carb 2500A; Canberra Packard, Groningen, The Netherlands).
Metabolite identification and structure elucidation. Incubation samples were analyzed by HPLC coupled with electrospray ionization MS in positive and negative ionization mode using a quadrupole time-of-flight mass spectrometer (Q-Star Pulsar; MDS Sciex, Toronto, ON, Canada). HPLC conditions were similar to those described for metabolite profiling. Conditions for mass spectral analysis were as follows: mass range of 50 to 1500 amu, nitrogen as nebulizer and desolvation gas, ambient source temperature, and ion source voltage of 5800 V. Collision-induced dissociation experiments (tandem mass spectrometry) were performed with collision energies of 20 to 60 eV. Metabolite structures were proposed after analysis of changes in molecular mass and interpretation of the fragmentation pattern, compared with the parent drug or the synthetic reference. All 1 H NMR spectra were obtained and recorded on a Bruker DRX 500 or a Bruker DRX 700 MHz spectrometer (Bruker, Rheinstetten, Germany).
Results

Turnover in Incubations.
Recovery of radioactivity from all in vitro incubations of [
14 C]rivaroxaban with liver microsomes and hepatocytes was Ͼ95%. Representative radiochromatograms from incubations with human liver microsomes and rat, dog, and human hepatocytes are shown in Figs. 2 and 3, respectively. The turnover of [ 14 C]rivaroxaban was in the range of 13 to 36% after 2 h of incubation with liver microsomes in the presence of NADPH and in the range of 37 to 60% after 24 h of incubation in hepatocyte cultures (Table 1 ). In incubations with liver microsomes without NADPH, the turnover of NADPH-independent hydrolytic reactions was in the range of 1 to 4%. Metabolite profiles were very similar in all species investigated. All radioactive metabolites and parent drug from all incubations were quantified (mass-balanced) ( Table 1) .
Metabolite Identification and Characterization. In addition to the parent drug, 18 metabolites were found and identified in all in vitro incubations. In addition, an impurity already present in the stock solutions of rivaroxaban (approximately 0.7%) was identified as a dechloro derivative of rivaroxaban. Metabolite structures were first elucidated by liquid chromatography-MS with detailed analysis of the changes in molecular mass and interpretation of the fragmentation patterns, compared with those of the parent drug (Table 2) . Major metabolites were isolated from incubations for further structure elucidation by 1 H NMR analysis. Finally, major metabolites were synthesized separately, and product ion spectra, 1 H NMR data, and retention times of the synthetic standard were compared with the compounds identified in in vitro incubations.
The product ion spectrum of [ 12 C]rivaroxaban, with a pseudomolecular ion, [M ϩ H] ϩ m/z 436, exhibited two major fragments of m/z 231 and 145. It was proposed that these fragments were obtained by cleavage of the oxazolidinone and the chlorothiophene amide moiety, respectively ( Table 2 ). The characteristic fragment m/z 145 (chlorothiophene carbonyl) is common to all radioactive metabolites identified, indicating that the chlorothiophene moiety remains intact.
The product ion spectra of metabolites M-1, M-2, M-3, M-5, M-7, M-8, M-10, and M-11 exhibited losses of 18 amu (H 2 O), 46 amu (HCOOH), 58 amu (HOCCOH), or 72 amu (CO 2 ϩ CO), indicating that metabolism occurred at the morpholinone moiety. In contrast, the hydroxylated metabolite M-9 showed a product ion spectrum that was characteristically different from that for the other hydroxylated me- dmd.aspetjournals.org tabolites, M-2, M-3, and M-8. In the case of metabolite M-9, fragmentation at the oxazolidinone moiety indicated that the hydroxylation had taken place at the oxazolidinone ring. The detailed proposed fragmentation for all metabolites is presented in Table 2 . Based on this structural information, reference material for metabolites M-1, M-2, M-4, M-7, M-9, M-13, M-15, M-16, M-17, and M-18 was synthesized, and structures of the metabolites were confirmed. It is interesting to note that the aldehyde derivative M-16 was only detected as an aldehyde hydrate in aqueous solution (Table 2) .
Metabolic Pathways. Several primary oxidative (NADPH-dependent) and hydrolytic (NADPH-independent) metabolic pathways were identified. Hydroxylation occurred at the morpholinone moiety, leading to metabolites M-2, M-3, and M-8, and at the oxazolidinone moiety, leading to metabolites M-9 and M-12. Metabolite M-12 is most likely to be formed by hydroxylation at the tertiary carbon atom of the oxazolidinone, followed by ring opening/rearrangement and loss of CO 2 . Bishydroxylations, combinations of morpholinone and oxazolidinone hydroxylation, leading to metabolites M-10 and M-11 were also identified. Among all oxidative reactions, the hydroxylation leading to M-2 was the major primary pathway identified in incubations with liver microsomes across all species, accounting for more than 60% of the total oxidative metabolism. M-2 could be further metabolized in a subsequent ring opening/oxidation step, leading to M-1, which was the major metabolite in all hepatocyte incubations. This reaction was well catalyzed with human liver cytosol in the presence of NAD ϩ , indicating the involvement of alcohol dehydrogenase (data not shown). Alternatively, M-2 could be reduced after ring opening, leading to M-5, which was found as a minor metabolite in all hepatocyte incubations.
In addition, two independent hydrolytic pathways were observed: amide hydrolysis at the morpholinone moiety, leading to metabolite M-7; and amide hydrolysis at the chlorothiophene moiety, leading to metabolite M-13. In hepatocytes, M-13 was not found because it was readily conjugated with glycine, leading to metabolite M-4. This hypothesis was demonstrated by incubation of M-13 with hepatocytes, for which the glycine conjugation was the only pathway found (data not shown). These hydrolytic pathways were more pronounced in hepatocyte incubations, accounting for approximately 18, 17, and 10% of total metabolism in human and dog and in rat, respectively. SCHEME 1. Proposed hydrolytic pathway for the cleavage of rivaroxaban. 14 C]rivaroxaban, leading to M-13 and subsequently to M-4, was of special interest to study because the radioactive 14 C label is located on the carbonyl moiety adjacent to the chlorothiophene moiety. Therefore, only M-4, but not the unlabeled part of the compound, is considered in 14 C-mass balance studies of rivaroxaban. The mechanism of cleavage and the metabolic fate of the unlabeled moiety of [ 14 C]rivaroxaban were studied by in vitro incubation of rivaroxaban with human liver cytosol, liver microsomes, and hepatocytes. Two mechanisms are possible for this cleavage: hydrolysis of the amide bond to form M-15 and M-13, and subsequent glycine conjugation, leading to M-4 (Scheme 1) or hydroxylation of the methylene group adjacent to the amide, followed by N-dealkylation, to form M-16 and M-14, which is further hydrolyzed to M-13 and then conjugated with glycine, leading to M-4 (Scheme 2). To investigate the possibility of this oxidative mechanism, rivaroxaban was incubated in the presence and absence of NADPH with human liver microsomes and recombinant CYP3A4, which was assigned to be the major enzyme involved in the formation of M-9. The details of this study will be published elsewhere (M. Radtke, C. Weinz, D. Lang, and A. Kern, manuscript in preparation) .
Incubations of rivaroxaban with liver cytosol showed no detectable formation of the postulated metabolites M-15 [(S)-oxamine] or the corresponding acid M-13. Incubations of rivaroxaban with liver microsomes, both with and without NADPH, showed a time-dependent formation of M-15, M-13, and M-16; formation of M-14 was not detected. However, traces of M-14 were formed in incubations with recombinant CYP3A4. The aldehyde M-16 was detected as an aldehyde hydrate. Incubations of M-13 and M-14 (10 g/ml) in human hepatocytes led to M-4 and unchanged M-14, respectively, indicating that M-14 cannot be hydrolyzed to M-13. All of these experiments provided strong evidence that the cleavage was hydrolytic.
Incubations of M-15 with liver microsomes, with and without the NADPH-generating system, only led to aldehyde M-16. After preincubation of human liver microsomes with irreversible inhibitors for MAO-A and MAO-B (0.1 M clorgyline and 0.1 M deprenyl, respectively) (Livingston and Livingston, 1996; Lee et al., 2003) In incubations with M-17 and M-18, no significant turnover or formation of further metabolites could be detected for either compound. These different experiments showed that for derivatives missing the chlorothiophene amide moiety no significant further oxidative metabolism occurs at the morpholinone moiety, as was the case for the parent drug. In addition, in incubations of rivaroxaban with hepatocytes, in which sufficient amounts of metabolites (e.g., M-1) were formed, none of the respective oxidative SCHEME 2. Proposed oxidative pathway for the cleavage of rivaroxaban. 
Discussion
In this article, the in vitro metabolism of rivaroxaban in liver microsomes and hepatocytes of rats, dogs, and humans has been elucidated to support safety and clinical studies. After incubation with [ 14 C]rivaroxaban, recovery of 14 C-activity was very high (Ͼ95%; in most cases approximately 100%), indicating no detectable covalent protein binding caused by bioactivation in vitro, as has been reported for other thiophene-containing compounds (Lecoeur et al., 1994; Valadon et al., 1996) . This high recovery of 14 C-activity also indicates that structure elucidation comprised all relevant metabolites. All species investigated exhibited very similar metabolite profiles and showed no significant species differences in metabolite formation. This result suggests that rats and dogs are suitable preclinical species for safety studies with respect to drug metabolism.
The main metabolic pathway identified by in vitro incubation of [ 14 C]rivaroxaban with liver microsomes and hepatocytes was oxidative metabolism at the morpholinone moiety and, to a minor extent, at the oxazolidinone moiety. In addition, hydrolytic pathways were identified, occurring at the morpholinone ring and the chlorothiophene amide moiety. Hydroxylation at the morpholinone moiety led to M-2 (main metabolite), M-3, and M-8. M-2 was further metabolized in a subsequent morpholinone ring opening/oxidation step, leading to M-1 (major metabolite) or in a ring opening/reduction step leading to M-5. M-9 was identified as the oxazolidinone hydroxylated metabolite. Amide hydrolysis at the morpholinone ring led to metabolite M-7, whereas amide hydrolysis at the chlorothiophene amide moiety led to metabolite M-13. In hepatocytes, M-13 was readily conjugated with glycine, leading to M-4. In dog and human hepatocytes, oxidative and hydrolytic pathways accounted for approximately 78 and 18% of total metabolism, respectively. More oxidative than hydrolytic metabolism was observed in rat hepatocytes (90 and 10% of total metabolism, respectively). The M-2 pathway (including M-1and M-5) accounted for Ͼ60% of total metabolism in all species. In man, CYP3A4 and CYP2J2 are the two enzymes responsible for the oxidative metabolism and contributed to a similar extent (manuscript in preparation). These findings are in good agreement with the metabolic pathways found in in vivo mass balance studies for these three species (Weinz et al., 2009) .
Cleavage of radiolabeled [ 14 C]rivaroxaban at the chlorothiophene amide moiety leads to metabolite M-13 and subsequently to M-4. The radioactive 14 C-label is located on the carbonyl moiety adjacent to the chlorothiophene moiety, and, therefore, only M-13 and M-4, but not the unlabeled part of the molecule, are considered in 14 C-mass balance studies of rivaroxaban. In this part of the current study we investigated the mechanism of this cleavage and the metabolic fate of the unlabeled moiety of rivaroxaban in vitro and identified all metabolites resulting from the different experiments performed.
Two mechanisms were theoretically possible. First, a hydrolytic pathway (NADPH-independent) would consist of the hydrolysis of the amide bond to form M-15 [(S)-oxamine] and M-13 (5-chlorothiophene-2-carboxylic acid, precursor of M-4) (Scheme 1). Second, an oxidative pathway (NADPH-dependent) would consist of the hydroxylation of the methylene group adjacent to the amide, followed by N-dealkylation, to SCHEME 3. The in vitro metabolism of rivaroxaban.
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M-15 formation in incubations without NADPH clearly indicated that the hydrolytic pathway (which should be NADPH-independent) was possible. The presence of M-16 could be explained by further metabolism of M-15 mediated by an NADPH-independent enzyme system or as an indication of the oxidative pathway. However, M-14 formation was not observed in these incubations; in addition, the fact that M-14 was not hydrolyzed into M-13 in incubations with human hepatocytes provides strong evidence that the mechanism is hydrolytic, with an amidase being most likely involved in this cleavage. M-4 formation was rapid in incubation of M-13 with human hepatocytes and was the only pathway found. The hydrolytic pathway is also supported by the in vivo data (Weinz et al., 2009) , with the formation of M-4 as the endpoint and no formation of M-14.
The enzyme catalyzing the subsequent, NADPH-independent oxidation of M-15 to M-16 observed in incubations with human liver microsomes was identified as MAO. This was demonstrated by inhibition studies with the MAO-A-and MAO-B-specific, irreversible inhibitors clorgyline and deprenyl. Furthermore, recombinant MAO-A and MAO-B catalyzed the formation of M-16.
Further evaluation of the fate of the unlabeled metabolite M-15 provides strong evidence that the alcohol M-17 and the carboxylic acid M-18 are the final products in the metabolism of M-15 in human hepatocytes, through the intermediate formation of the aldehyde M-16 and no further oxidative metabolism at the morpholinone moiety. This is in good agreement with the human in vivo data (Weinz et al., 2009) .
In summary, the metabolic pathways involved in the in vitro metabolism of rivaroxaban have been identified (Scheme 3). Taking all in vitro investigations into account, the metabolic pathways in hepatocytes in sandwich cultures are in very good agreement with the pathways observed in vivo (Weinz et al., 2009) . No major species differences were observed in the in vitro metabolism of [ 14 C]rivaroxaban, and no reactive metabolite was found. In separate studies, it has been shown that the metabolism of rivaroxaban does not involve metabolites with significant pharmacological activity, which is in good agreement with the strong correlation of FXa activity and plasma concentration of rivaroxaban in clinical studies (Kubitza et al., 2005a,b) . Because of its metabolism via oxidative and hydrolytic pathways, involving different classes of enzymes, rivaroxaban should be less prone to drug-drug interactions.
